

accellta is a commercial stage stem cell company which offers a range of revolutionary solutions for industrializing stem cells. We at Accellta aim to use our novel and proprietary technologies for stem cells growth and differentiation in very high quantities not just for therapeutics but also for the food-tech market. **That is why we created MEATHOS - a spinoff focused on cultured meat.**

MEATHOS

Upscaling Cultured Meat

is an Israeli-based biotechnology company aiming to produce cultured-meat. Our final product is **100% BOVINE MINCED MEAT** composed from muscle, fat & blood cells, therefore mimics the sensory experience and nutritional values of conventional meat. Meathos product will achieve **price parity with conventional meat** by using Accellta's disruptive technology.

THE NEED

By 2050 meat consumption will double to feed >10 billion people. To supply the enormous demand, and to achieve **price parity** with conventional meat - production must occur at **INDUSTRIAL SCALE**.

MEATHOS SOLUTION

Meathos mother company holds unique suspension media and culturing technologies enabling **MASS PRODUCTION & CONTROLLED DIFFERENTIATION** of stem cells w/o genetic modification in 3D carrier-free suspension culture. The product price is expected to be 10\$/KG in 2023 and 5\$/KG in 2024.

These technologies lead to a **20-fold increase in production efficiency** and **50-fold cost reduction**.

BUSINESS MODEL

Industry: **Food-Tech, cultured meat**
Market Size: **1.7T\$**
(60% of the meat is consumed as minced)
Stage: **Pre-Seed**
Investment opportunity: **750K\$**
Model: **SAFE**

Main product | Bovine minced meat.
Pipeline product | Bovine premium steak, porcine meat.
Establishment of manufacturing plant.
🔧 Possibility for Sub-licensing agreements
🔧 In the first 7 months - process development by Accellta
🔧 Facility will be established following 7 months of development

COMPETITIVE ADVANTAGE

- 🔧 Final product is 100% real meat.
- 🔧 Cost-effective and scalable solution.
- 🔧 Technological platform - enabling cultured meat production from any source.
- 🔧 One of the only companies holding bovine embryonic stem cells & relevant IP for their derivation.
- 🔧 Proprietary serum-free, cheap media for stem cell culture culturing.

ACHIEVEMENTS

- 🔧 Patented-pending methods for bovine ESCs derivation and iPSC generation, and serum-free media for bovine suspension culture.
- 🔧 MCB and ongoing culture of bovine embryonic and induced PSC lines.
- 🔧 Suspension culture of bovine stem cells.

TEAM

Michal Amit (Accellta), PhD | CSO
Rappaport Faculty of Medicine, Technion.
World-renown stem cells researcher more than 20 years of experience.
1st in Israel to culture ESCs & third worldwide.
Numerous publications in key scientific journals; Dozens of patents.
Hagit Domev-Cohen (Accellta) PhD, MBA | Project Manager
Ort Braude College of Engineering.
Rappaport Faculty of Medicine, Technion.
A senior research scientist with over 10 years of broad experience in stem cell technologies

TBD (Meathos team)
Product Manager
Food engineer
2 experienced scientists

Contact us

michala@accellta.com
www.accellta.com